Lifestyle and Alzheimer’s Disease In Down Syndrome- Life Stressors Supplement

生活方式和唐氏综合症中的阿尔茨海默病 - 生活压力补充剂

基本信息

  • 批准号:
    10839520
  • 负责人:
  • 金额:
    $ 10.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-15 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY People with Down syndrome (DS) evidence an overproduction of amyloid-beta (Aβ), due to having three copies of chromosome 21. With age, Aβ aggregates into extracellular brain plaques, which is a hallmark feature of Alzheimer’s disease (AD); however, there is variability in the age at which this AD pathology begins and how clinical AD symptomology unfolds in DS. Stressful life experiences, both in childhood and in adulthood, are associated with aging-related cognitive decline and risk of sporadic late onset AD outside of DS. Stressful life experiences may exacerbate AD pathology and/or its effects on cognition through inflammation, and/or by contributing to conditions (e.g., obesity, cardiovascular disease, depression, sleep disorders) that are known risk factors for AD. The goal of the Administrative Supplement, “Life Stressors and Alzheimer’s Disease in Down syndrome,” is to expand on the R01AG70028 “Lifestyle Risk and Resiliency Factors and Alzheimer’s Disease in Down syndrome” project to examine the effect of adverse childhood events (e.g., parent divorce, abuse/neglect, poverty) and recent life stressors (e.g., job termination, new staff, death of family member) on the timing of AD pathology and symptomology in people with Down syndrome. Specifically, this supplement will: 1) include a new measure into the Lifestyle R01 protocol to capture adverse childhood experiences (ACEs); 2) use a new coding technique to capture stressful life events in adulthood; and 3) conduct new analyses to determine the association between stressful childhood and adult life experiences and AD imaging and biofluid biomarkers and cognitive impairments. The parent R01 follows 180 adults with DS who are co-enrolled in the NIH-funded Alzheimer’s Biomarker Consortium in DS (ABC-DS), in which AD biomarkers (e.g., PET Aβ, and tau, CSF Aβ42, and plasma p-tau 217), cognitive functioning, and dementia status are collected. The parent Lifestyle R01 collects three time points of data, aligning with ABC-DS cycles, and focuses on four modifiable lifestyle factors – physical activity, sleep, cognitive stimulation, and social engagement. The “Life Stressors and Alzheimer’s Disease in Down syndrome” Administrative Supplement will build on these aims by generating novel and significant information on the effect of life stressors on AD in DS that can drive social policy and interventions in the future.
项目摘要 唐氏综合征(DS)患者的证据表明,由于有三个β淀粉样蛋白(Aβ), 21号染色体的拷贝。随着年龄的增长,Aβ聚集成细胞外脑斑块,这是一个标志, 阿尔茨海默病(AD)的一个特征;然而,这种AD病理开始的年龄存在变异性 以及临床AD病理学如何在DS中展开。压力的生活经历,无论是在童年和 与年龄相关的认知能力下降和DS以外的散发性迟发性AD风险相关。 应激性生活经历可能会加剧AD病理和/或其通过炎症对认知的影响, 和/或通过促成条件(例如,肥胖症、心血管疾病、抑郁症、睡眠障碍), 已知的AD风险因素。 行政补充的目标,“生活压力和阿尔茨海默氏病的唐氏综合征,”是 扩展R 01 AG 70028“生活方式风险和恢复力因素与阿尔茨海默病在下 综合征”项目,以检查不良儿童事件的影响(例如,父母离婚,虐待/忽视, 贫困)和最近的生活压力(例如,工作终止、新员工、家庭成员死亡)对AD时间的影响 唐氏综合症患者的病理学和病理学。具体而言,该补充将:1)包括 生活方式R 01方案中的新措施,以捕获不良儿童经历(ACE); 2)使用新的 编码技术,以捕捉成年期的压力生活事件; 3)进行新的分析,以确定 压力性童年和成年生活经历与AD成像和生物流体生物标志物之间的关联 和认知障碍。 父母R 01跟随180名患有DS的成年人,他们共同参加了NIH资助的阿尔茨海默氏症生物标志物 DS联合会(ABC-DS),其中AD生物标志物(例如,PET Aβ和tau、CSF Aβ42和血浆p-tau 217),认知功能和痴呆状态。父生活方式R 01收集三次 数据点,与ABC-DS周期一致,并侧重于四个可改变的生活方式因素-身体活动, 睡眠、认知刺激和社会参与。生活压力与阿尔茨海默病 综合征”行政补编将在这些目标的基础上, 生活压力对DS中AD的影响,可以推动未来的社会政策和干预措施。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sigan L Hartley其他文献

Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study
利用血浆生物标志物预测唐氏综合征患者的淀粉样蛋白和tau 蛋白脑沉积及认知能力下降:一项纵向队列研究
  • DOI:
    10.1016/s1474-4422(25)00158-9
  • 发表时间:
    2025-07-01
  • 期刊:
  • 影响因子:
    45.500
  • 作者:
    Shorena Janelidze;Lyduine E Collij;Niklas Mattsson-Carlgren;Alex Antill;Charles M Laymon;Ira Lott;H Diana Rosas;Davneet S Minhas;Weiquan Luo;Shahid Zaman;Alzheimer's Biomarker Consortium–Down Syndrome investigators;Mark Mapstone;Elizabeth Head;Florence Lai;Sigan L Hartley;Beau M Ances;Sharon J Krinsky-McHale;Joseph H Lee;Rik Ossenkoppele;Bradley T Christian;Benjamin L Handen;Oskar Hansson
  • 通讯作者:
    Oskar Hansson
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study
唐氏综合征患者症状性阿尔茨海默病的时间线(通过淀粉样蛋白-PET 和 tau-PET 评估):一项纵向队列研究
  • DOI:
    10.1016/s1474-4422(24)00426-5
  • 发表时间:
    2024-12-01
  • 期刊:
  • 影响因子:
    45.500
  • 作者:
    Emily K Schworer;Matthew D Zammit;Jiebiao Wang;Benjamin L Handen;Tobey Betthauser;Charles M Laymon;Dana L Tudorascu;Annie D Cohen;Shahid H Zaman;Beau M Ances;Mark Mapstone;Elizabeth Head;Bradley T Christian;Sigan L Hartley;Howard Aizenstein;Beau Ances;Howard Andrews;Karen Bell;Rasmus Birn;Adam Brickman;Fan Zhang
  • 通讯作者:
    Fan Zhang

Sigan L Hartley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sigan L Hartley', 18)}}的其他基金

Lifestyle and Alzheimer's Disease In Down Syndrome
生活方式与唐氏综合症中的阿尔茨海默病
  • 批准号:
    10098587
  • 财政年份:
    2020
  • 资助金额:
    $ 10.52万
  • 项目类别:
Lifestyle and Alzheimer's Disease In Down Syndrome
生活方式与唐氏综合症中的阿尔茨海默病
  • 批准号:
    10263355
  • 财政年份:
    2020
  • 资助金额:
    $ 10.52万
  • 项目类别:
Lifestyle and Alzheimer's Disease In Down Syndrome
生活方式与唐氏综合症中的阿尔茨海默病
  • 批准号:
    10474454
  • 财政年份:
    2020
  • 资助金额:
    $ 10.52万
  • 项目类别:
Lifestyle Risk and Resiliency Factors and Alzheimer’s Disease in Down syndrome
唐氏综合症中的生活方式风险和弹性因素以及阿尔茨海默病
  • 批准号:
    10669953
  • 财政年份:
    2020
  • 资助金额:
    $ 10.52万
  • 项目类别:
Lifestyle and Alzheimer's Disease In Down Syndrome
生活方式与唐氏综合症中的阿尔茨海默病
  • 批准号:
    10696137
  • 财政年份:
    2020
  • 资助金额:
    $ 10.52万
  • 项目类别:
Family Outcomes in Autism Spectrum Disorders
自闭症谱系障碍的家庭结局
  • 批准号:
    9223757
  • 财政年份:
    2013
  • 资助金额:
    $ 10.52万
  • 项目类别:
Family Outcomes in Autism Spectrum Disorders
自闭症谱系障碍的家庭结局
  • 批准号:
    8524248
  • 财政年份:
    2013
  • 资助金额:
    $ 10.52万
  • 项目类别:
Family Outcomes in Autism Spectrum Disorders
自闭症谱系障碍的家庭结局
  • 批准号:
    8666667
  • 财政年份:
    2013
  • 资助金额:
    $ 10.52万
  • 项目类别:
Family Outcomes in Autism Spectrum Disorders
自闭症谱系障碍的家庭结局
  • 批准号:
    8806603
  • 财政年份:
    2013
  • 资助金额:
    $ 10.52万
  • 项目类别:
Post-Doctoral Training in Intellectual and Developmental Disabilities Research
智力和发育障碍研究博士后培训
  • 批准号:
    10395978
  • 财政年份:
    1995
  • 资助金额:
    $ 10.52万
  • 项目类别:

相似海外基金

A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement)
无家可归者使用芬太尼兴奋剂多物质的纵向定性研究(行政补充)
  • 批准号:
    10841820
  • 财政年份:
    2023
  • 资助金额:
    $ 10.52万
  • 项目类别:
Proton-secreting epithelial cells as key modulators of epididymal mucosal immunity - Administrative Supplement
质子分泌上皮细胞作为附睾粘膜免疫的关键调节剂 - 行政补充
  • 批准号:
    10833895
  • 财政年份:
    2023
  • 资助金额:
    $ 10.52万
  • 项目类别:
Administrative Supplement: Life-Space and Activity Digital Markers for Detection of Cognitive Decline in Community-Dwelling Older Adults: The RAMS Study
行政补充:用于检测社区老年人认知衰退的生活空间和活动数字标记:RAMS 研究
  • 批准号:
    10844667
  • 财政年份:
    2023
  • 资助金额:
    $ 10.52万
  • 项目类别:
StrokeNet Administrative Supplement for the Funding Extension
StrokeNet 资助延期行政补充文件
  • 批准号:
    10850135
  • 财政年份:
    2023
  • 资助金额:
    $ 10.52万
  • 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
  • 批准号:
    10896844
  • 财政年份:
    2023
  • 资助金额:
    $ 10.52万
  • 项目类别:
Biomarkers of Disease in Alcoholic Hepatitis Administrative Supplement
酒精性肝炎行政补充剂中疾病的生物标志物
  • 批准号:
    10840220
  • 财政年份:
    2023
  • 资助金额:
    $ 10.52万
  • 项目类别:
Administrative Supplement: Improving Inference of Genetic Architecture and Selection with African Genomes
行政补充:利用非洲基因组改进遗传结构的推断和选择
  • 批准号:
    10891050
  • 财政年份:
    2023
  • 资助金额:
    $ 10.52万
  • 项目类别:
Power-Up Study Administrative Supplement to Promote Diversity
促进多元化的 Power-Up 研究行政补充
  • 批准号:
    10711717
  • 财政年份:
    2023
  • 资助金额:
    $ 10.52万
  • 项目类别:
Administrative Supplement for Peer-Delivered and Technology-Assisted Integrated Illness Management and Recovery
同行交付和技术辅助的综合疾病管理和康复的行政补充
  • 批准号:
    10811292
  • 财政年份:
    2023
  • 资助金额:
    $ 10.52万
  • 项目类别:
Sedentary behavior, physical activity, and 24-hour behavior in pregnancy and offspring health: the Pregnancy 24/7 Offspring Study Administrative Supplement
久坐行为、体力活动和 24 小时行为对怀孕和后代健康的影响:怀孕 24/7 后代研究行政补充
  • 批准号:
    10893074
  • 财政年份:
    2023
  • 资助金额:
    $ 10.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了